L'institut Domaines de recherche Plates-formes techniques Venir à l'INM. Pourquoi? Actu / presse

U844

 

U1051

Equipe 1
Génétique et thérapies des cécités rétiniennes et du nerf optique

Equipe 2
Surdité, acouphènes et thérapies

Equipe 3
Différentiation neurale et connectivité dans le système
somato-sensoriel

Equipe 4
Plasticité, cellules souches et gliomes

Equipe 5
Pathologie du motoneurone : voies de signalisation et thérapies

Equipe Avenir 1
Spécification somato-sensorielle

Equipe Avenir 2
Myélinisation/démyélinisation dans le système nerveux

Equipe Avenir 3
Le système Ubiquitine Protéasome dans la neurodégénérescence et l'architecture du cytosquelette

 

 

| Accueil | Contact | Légal |    

Domaines de recherche

Equipe AVENIR 3

The Ubiquitin Proteasome System in
neurodegeneration and cytoskeleton architecture


Group leader
Pascale BOMONT

pascale.bomont@inserm.fr
Tel +33 (0)4 99 63 60 73

Members

Scientists
Pascale BOMONT

Postdoctoral fellows
Prasanna Iyengar

PhD student
André Lopes

Master students
Marion PEYRESSATRE

Engineers
Alexia BOIZOT

 

 


The Ubiquitin Proteasome System (UPS) is impaired in many neurodegenerative disorders and its role in neurodegeneration is the focus of intense scrutiny. However, solving its implication in neuronal death represents a considerable challenge and systems in which neurodegeneration is directly caused by mutations in component(s) of the UPS are very valuable models for this aim.

The identification of gigaxonin, the substrate adaptor of a Cul3-E3 ubiquitin ligase, as the defective protein in the fatal neurodegenerative disorder Giant Axonal Neuropathy (GAN), prompted us to choose this model as a direct way to study the role of the UPS in neurodegeneration. The broad degeneration of the nervous system together with the generalized disorganization of Intermediate Filaments in patients, point to a key role for gigaxonin in sustaining both neuronal survival and cytoskeleton architecture.

Our group is dedicated to deciphering the pathophysiology of GAN but also to developing a specific diagnostic test and the first therapeutic approaches for this fatal disease. We are studying the pathways of cell death and cytoskeleton dynamics in new neuronal models that are also used as readout tests to evaluate the efficacy of therapeutic vehicules generated by our collaborators. We are using multidisciplinary approaches encompassing human genetics, cell biology, biochemistry and animal models.

 


Main publications:


Ganay T, Boizot A, Burrer R, Chauvin JP, and Bomont P. Sensory-motor deficits and Neurofilament disorganization in Gigaxonin-null mice. Mol Neurodegener.12;6:25. (2011)


Cleveland DW, Yamanaka K, Bomont P. (2009) Gigaxonin controls vimentin organization through a tubulin chaperone-independent pathway. Hum Mol Genet. 18(8):1384-94. (2009)


Bomont P
, Koenig M. (2003). Intermediate filament aggregation in fibroblasts of giant axonal neuropathy patients is aggravated in non dividing cells and by microtubule destabilization. Hum Mol Genet. 12(8):813-22. (2003)


Bomont P
, Cavalier L, Blondeau F et al. The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy. Nat Genet. 26(3):370-4. (2000)

Full publication record:

http://www.ncbi.nlm.nih.gov/pubmed
/?term=bomont+p

 

 

         
         

 

L'institut | Domaines de recherche | Plates-formes techniques |
Venir à l'INM. Pourquoi? | Actu / Presse | Contact |
Accueil | Site map |  Légal & crédits
Directeur de publication: Christian Hamel
Copyright © INM 2006